Inhibition of p38-mitogen-activated protein kinase may protect from clozapine-induced agranulocytosis.
Loeffler
Stefan
S
Fehsel
Karin
K
Krieger
Klaus
K
Henning
Uwe
U
Klimke
Ansgar
A
D000380:Agranulocytosis / Q000139:chemically induced* / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000187:drug effects; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D017382:Reactive Oxygen Species / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy; D012702:Serotonin Antagonists / Q000009:adverse effects*; D048051:p38 Mitogen-Activated Protein Kinases
D000970:Antineoplastic Agents; D017382:Reactive Oxygen Species; D012702:Serotonin Antagonists; D016179:Granulocyte Colony-Stimulating Factor; D019833:Genistein; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D003024:Clozapine